Biomarkers for Alzheimer's disease detectable through structural MRI primarily include gray matter, white matter, and cerebrospinal fluid (CSF). While amyloid plaques are recognized as significant biomarkers, they cannot be identified using structural MRI. The relationship between changes in gray matter, white matter, and CSF is complex, and while these features can suggest the presence of Alzheimer's, they are not definitive for diagnosis. Diagnosis typically involves a comprehensive assessment, including patient history, cognitive testing, and exclusion of other conditions, as brain scans alone cannot confirm Alzheimer's. The diagnostic process is intricate, often requiring multiple tests to rule out other causes of symptoms, and definitive diagnosis is usually only possible post-mortem. Changes observed in scans may also be age-related and present in individuals without dementia. CSF examination is infrequently used due to its invasive nature, despite its potential to reveal inflammatory markers. Overall, while imaging plays a role in research and diagnosis, it is not a standalone solution.